{"id":378953,"date":"2023-12-13T16:15:32","date_gmt":"2023-12-13T21:15:32","guid":{"rendered":"https:\/\/platohealth.ai\/nmdp-be-the-match-ptcy-research-levels-the-field-between-matched-and-mismatched-hematopoietic-cell-transplantation-medical-device-news-magazine\/"},"modified":"2023-12-14T05:35:03","modified_gmt":"2023-12-14T10:35:03","slug":"nmdp-be-the-match-ptcy-research-levels-the-field-between-matched-and-mismatched-hematopoietic-cell-transplantation-medical-device-news-magazine","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/nmdp-be-the-match-ptcy-research-levels-the-field-between-matched-and-mismatched-hematopoietic-cell-transplantation-medical-device-news-magazine\/","title":{"rendered":"NMDP\/Be The Match\u00ae PTCy Research Levels The Field Between Matched And Mismatched Hematopoietic Cell Transplantation – Medical Device News Magazine","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

Underscoring its commitment to expanding access to cell and gene therapy, NMDP\/Be The Match\u00ae<\/span><\/a> presented research today at the American Society of Hematology (ASH) Annual Meeting & Exhibition<\/span><\/a>, which demonstrated that the use of post-transplant cyclophosphamide (PTCy) based graft-versus-host disease (GvHD) prevention significantly reduces the risk of transplant across the human leukocyte antigen (HLA) barrier and has the potential to level the playing field for patients with mismatched donors.\u00a0<\/span><\/p>\n

The study shows the practice-changing potential of using mismatched unrelated donors (MMUD) to expand access to all patients regardless of ancestry. For populations currently facing the lowest odds of finding a fully matched donor, this could result in a nearly three-fold increase in the likelihood of securing a suitable donor and offering cell transplantation as a viable, life-saving therapy.<\/p>\n

\u201cHistorically, transplant outcomes following MMUD hematopoietic cell transplantation (HCT) using calcineurin inhibitor (CNI)-based GvHD prophylaxis have been poor,\u201d said Dr. Jeff<\/span>er<\/span>y Auletta, Senior Vice President, NMDP<\/span>\/Be The Match<\/span>and Chief Scientific Director, CIBMTR<\/span><\/a>\u00ae\u00a0(Center for International Blood and Marrow Transplant Research\u00ae). \u201c<\/span>However, PTCy has transformed the allogeneic HCT landscape, enabling successful use of mismatched related and unrelated donor HCT by transcending the HLA barrier. This research not only confirms the efficacy of PTCy, but also alludes to its promise to provide allogeneic HCT to essentially all patients irrespective of their ancestry. That promise is a message of hope to our patients.\u201d<\/p>\n

The study, \u201cPost-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8\/8 Matched and 7\/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies,\u201d shows that this approach could significantly expand access to allogeneic HCT for patients of various ancestries, as finding a fully matched donor is no longer crucial for successful outcomes. It also suggests that although 8\/8 URD HCT remains the best option if available, a 7\/8 URD and haploidentical-related BMT donor are viable alternatives that warrant further comparative study. In summary, study results indicated that with PTCy GvHD prophylaxis:<\/p>\n